Overview

An Open Label, Safety and Tolerability Continuation Study of Intracerebroventricular Administration of sNN0029 to Patients With Amyotrophic Lateral Sclerosis

Status:
Terminated

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

This is an open label safety and tolerability continuation study of intracerebroventricular administration of sNN0029, containing the growth factor VEGF165, in patients with amyotrophic lateral sclerosis that have previously participated in study sNN0029-001. The intention of the study is to investigate safety and tolerability of intracerebroventricular administration of sNN0029 and whether it can improve motor function and prolong survival in patients with ALS.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Newron Sweden AB

Collaborators:

ICON Clinical Research
Medtronic